Africa Eastern and Southern vs Ireland: Antiretroviral therapy coverage for PMTCT
Africa Eastern and Southern
91.2%
in 2024
Ireland
100.0%
in 2024
Africa Eastern and Southern rank
1st
Ireland rank
1st
Antiretroviral therapy coverage for PMTCT over time
- Africa Eastern and Southern
- Ireland
How they compare
Ireland currently reports 100.0% against 91.2% in Africa Eastern and Southern, a difference of 8.8%.
That makes Ireland's figure about 1.1 times Africa Eastern and Southern's.
Across all 19 years both countries report, Ireland has been ahead every year.
Africa Eastern and Southern ranks 1st and Ireland ranks 1st of 15 groups.
Ireland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Africa Eastern and Southern | Ireland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 22.6% | 90.0% | 67.4% | Ireland |
| 2010s | 87.6% | 100.0% | 12.4% | Ireland |
| 2020s | 90.5% | 100.0% | 9.5% | Ireland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Africa Eastern and Southern or Ireland?
- Ireland, at 100.0% against 91.2% in Africa Eastern and Southern as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Africa Eastern and Southern and Ireland?
- 8.8%, with Ireland ahead.
- How many years of comparable data are there for Africa Eastern and Southern and Ireland?
- 19 years are reported by both, from 2000 to 2024.
- How do Africa Eastern and Southern and Ireland rank globally for antiretroviral therapy coverage for pmtct?
- Africa Eastern and Southern ranks 1st and Ireland ranks 1st of 15 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).